1. Market Research
  2. > Pathology
Customer Support

Talk to Ahmad

+1 718 618 4302

Industries

About 300 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Blood Cancer Therapeutics: Global Markets to 2023

  • $ 5500
  • December 2018
  • 174 pages

This report forecasts the global market by disease area and discusses market data for leukemia, lymphoma and myeloma.

  • Cancer
  • Leukemia
  • Lymphoma
  • Pathology
  • World

Chronic Lymphocytic Leukemia - Competitive Landscape to 2030

  • $ 3495
  • May 2020
  • 55 pages

Lung Cancer Breast Cancer Leukemia Lymphoma Non-Small Cell Lung...

  • Leukemia
  • Lymphoma
  • AbbVie Inc.
  • AstraZeneca PLC
  • Roche Group

T-Cell Immunotherapy Market (3rd Edition), 2018-2030

  • $ 3499
  • April 2018
  • 850 pages

LEUKEMIA AND LYMPHOMA ##. ##. ##. ##.

  • Immunotherapy
  • Leukemia
  • Lymphoma
  • Pharmaceutical
  • Therapy

Market Spotlight: Tumor Lysis Syndrome (TLS)

  • $ 16500
  • March 2018
  • 33 pages

& nbsp; Key Takeaways& nbsp; Datamonitor Healthcare estimates that in 2016, there were approximately ##, ## incident cases of tumor lysis syndrome (TLS) worldwide among individuals with high-risk malignancies (acute myeloid leukemia, acute lymphocytic leukemia, and Burkitt’s lymphoma)

  • Cancer
  • Leukemia
  • Lymphoma
  • United States
  • World

Leukemia & Lymphoma Society Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • November 2018
  • 42 pages

Sutro intends to use the funding for a Phase I study, initiated in April of this year, to evaluate STRO-## for treating multiple myeloma, diffuse large B-cell lymphoma, mantle cell lymphoma andindolent lymphomas, such asfollicular lymphoma.

  • Cancer
  • Leukemia
  • Lymphoma
  • Pharmaceutical
  • Therapy

Global Pediatric Proton Therapy Market & Forecast (10 Countries Market Data), Patients Treated

  • $ 2200
  • August 2017
  • 330 pages

For sarcomas and lymphomas, proton therapy may also deliver less radiation to the heart, lungs, and intestines.

  • Leukemia
  • Lymphoma
  • North America
  • United States
  • Forecast

Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2029

  • $ 10995
  • June 2020
  • 139 pages

LYMPHOMAS GO-2032C GSK-## CHIMERIX INC EXCELLTHERA INC FUJIFILM HOLDINGS CORP FUJIFILM HOLDINGS CORP AVEO ONCOLOGY INC MACROGENICS INC SYNIMMUNE GMBH CHONGQING PRECISION BIOTECH CO LTD PERSONGEN BIOMEDICINE SUZHOU CO LTD PERSONGEN BIOMEDICINE SUZHOU CO LTD GENUS ONCOLOGY LLC GLAXOSMITH

  • Chemotherapy
  • Leukemia
  • Lymphoma
  • Therapy
  • Novartis AG

Potential Pipeline Disruptors

  • $ 4200
  • May 2017
  • 120 pages

FOLLICULAR LYMPHOMA TENDS TO BE INDOLENT AND DIFFUSE LYMPHOMA TENDS TO BE AGGRESSIVE.

  • Leukemia
  • Lymphoma
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy

Global CML Market Report - 2022

  • $ 3849
  • June 2018
  • 82 pages

Imatinib mesylate is licensed as a firstline treatment for adults with chronic-phase Ph+ CML, and for the management of GIST, and as salvage therapy for Ph+ acute lymphoblastic lymphoma.

  • Leukemia
  • Lymphoma
  • Therapy
  • Incyte Corporation
  • Merck & Co., Inc.

Hematologic Malignancies Market Analysis by Type, By Therapy And Segment Forecasts, 2014 - 2025

  • $ 5950
  • September 2017
  • 113 pages

LymphomaLymphoma Market estimates and forecast, 2014 - 2025 (USD Billion) ##. ## Multiple Myeloma • Multiple myeloma Market estimates and forecast, 2014 - 2025 (USD Billion) ##. ## Others • Others Market estimates and forecast, 2014 - 2025 (USD Billion) Chapter ## Hematologic Malignanc

  • Cancer
  • Leukemia
  • Lymphoma
  • Pathology
  • United States

Oncology Drug Report: Zydelig | Idelalisib – 2011 -2016 analysis; 2017-2021 expectations

  • $ 308
  • January 2017
  • 52 pages

LONG-TERM DATA IN CLL kemia, follicular lymphoma and small lymphocytic lymphoma: PRESS RELEASE ## ## Sep 2014 European Commission grants Marketing Authorization for Gilead' s Zydelig® (idelalisib) for the treatment of chronic lymphocytic leukemia and follicular

  • Leukemia
  • Lymphoma
  • Therapy
  • United States
  • Gilead Sciences, Inc.

The Leukemia & Lymphoma Society Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • November 2017
  • 39 pages

Sutro intends to use the funding for a Phase I study, initiated in April of this year, to evaluate STRO-## for treating multiple myeloma, diffuse large B-cell lymphoma, mantle cell lymphoma andindolent lymphomas, such asfollicular lymphoma.

  • Cancer
  • Leukemia
  • Lymphoma
  • Pharmaceutical
  • Therapy

Potential "Pipeline Disruptors" - New Products That Will Drive The Future Pharmaceutical Market

  • $ 4200
  • May 2017
  • 120 pages

(% market share) CHAPTER ##: PIPELINE DISRUPTORS: LYMPHOMA MARKET OPPORTUNITY Non-Hodgkin' s Lymphoma Table ##-##: Classification of Non-Hodgkin' s Lymphomas Hodgkin' s Lymphoma Figure ##-##: Global Incidence and Mortality of Lymphoma by Country, 2012* THE HEAVY HITT

  • Leukemia
  • Lymphoma
  • Monoclonal Antibody
  • Pathology
  • Targeted Therapy

Acute Myeloid Leukemia - Epidemiology Forecast to 2029

  • $ 3995
  • June 2020
  • 37 pages

Acute Myeloid Leukemia - Epidemiology Forecast to 2029 Summary Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow in which the bone marrow produces abnormal red blood cells, white blood ...

  • Cancer
  • Epidemiology
  • Leukemia
  • Lymphoma
  • Forecast

Leukemia Treatment Drugs Industry Forecasts - China Focus

  • $ 1800
  • May 2020
  • 95 pages

It is mainly used in clinical acute promyelocytic leukemia, acute monocytic leukemia, acute myeloid leukemia and malignant lymphoma, etc.

  • Hormone
  • Leukemia
  • Lymphoma
  • China
  • Demand

Leukemia Treatment Drugs Companies in China

  • $ 1800
  • May 2020
  • 140 pages

For example, certain cases of ALL are associated with viral infections by either the human immunodeficiency virus or human T-lymphotropic virus (HTLV-## and -##, causing adult T-cell leukemia/ lymphoma).

  • Leukemia
  • Lymphoma
  • Pharmaceutical
  • China
  • Zhejiang Expressway Co., Ltd.

Leukemia Treatment Drugs Markets in China

  • $ 4000
  • May 2020
  • 290 pages

It is mainly used in clinical acute promyelocytic leukemia, acute monocytic leukemia, acute myeloid leukemia and malignant lymphoma, etc.

  • Anti-Infective
  • Hormone
  • Leukemia
  • Lymphoma
  • China

Blood Disease Drugs Industry Forecasts - China Focus

  • $ 1800
  • October 2019
  • 145 pages

Blood Disease Drugs Industry Forecasts - China Focus Published by Asia Market Info and Dev Co.

  • Blood Disease
  • Leukemia
  • Lymphoma
  • Therapy
  • China

Venclexta 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 21 pages

Venclexta 2018 U. S.

  • Cancer
  • Leukemia
  • Lymphoma
  • Pathology
  • United States

Venclexta

  • $ 10000
  • January 2019
  • 45 pages

Analyst Outlook Venclexta (venetoclax; AbbVie/ Roche) is a novel B-cell lymphoma ## (BCL-##) inhibitor that received an accelerated US Food and Drug Administration (FDA) approval for the second-line treatment of chronic lymphocytic leukemia (CLL) patients with deletion of the short arm of

  • Cancer
  • Leukemia
  • Lymphoma
  • Pathology
  • United States
View report >

Cancer Statistics in the US

  • January 2017
  • 28 pages

Estimated New Cases of Lymphoma, by Gender, 2017 ## Table ##.

  • Cancer
  • Leukemia
  • Lymphoma
  • United States
  • American Cancer Society, Inc.

Leukemia Statistics January 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on